RxDoctor Payments Data

Ken Park, MD

Internal Medicine · McKinney, TXNPI 1316980295

Payments from drug & device makers

$467in general payments, 2019–2025

Across 17 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$107
  • Abbott$86
  • Astellas Pharma US Inc$85
  • Otsuka America Pharmaceutical, Inc.$78
  • Exact Sciences$20
  • Novartis$19
  • plus $72 from 5 others

What the payments were for

  • Food & beverage$38282%
  • Education$8518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$467 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$301,202
Medicare patients
595
Services billed
3,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$83,638
OzempicSemaglutide61$79,876
EliquisApixaban95$76,177
ProliaDenosumab26$45,283
TradjentaLinagliptin38$41,613
XareltoRivaroxaban30$38,550
JanuviaSitagliptin Phosphate28$32,128
FarxigaDapagliflozin Propanediol24$27,134
RestasisCyclosporine20$19,545
MyrbetriqMirabegron19$18,069
JanumetSitagliptin Phos/Metformin Hcl11$17,469
Glatiramer Acetate12$13,801
LinzessLinaclotide15$13,646
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$13,386
LokelmaSodium Zirconium Cyclosilicate16$11,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$79,87661 claims
PfizerEliquis$19$76,17795 claims
AbbVieRestasis, Linzess$11$33,19135 claims
Astellas Pharma US IncMyrbetriq$85$18,06919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →